Answers are grounded in this paper and cite their sources.
Docetaxel (DTX) is a chemotherapeutic agent widely used in the treatment of solid tumors; however, its clinical application is limited by poor aqueous solubility, rapid systemic distribution, and dose-dependent toxicity. Dexamethasone (DEX) is commonly coadministered to reduce adverse effects associated with taxane-based therapies. In this study, a polysaccharide-based codelivery system was proposed to improve the controlled release and therapeutic performance of both drugs. Microcapsules were developed using the spray-drying technique, employing galactomannan extracted from Dimorphandra mollis as the polymeric matrix and incorporating an oil-in-water nanoemulsion based on Syagrus coronata oil loaded with both drugs. The systems were characterized in terms of structural morphology, thermal properties, encapsulation efficiency, in vitro cytotoxicity, and release profile. The results demonstrated the formation of amorphization within the polymeric matrix, as well as the formation of spherical microcapsules containing the drug-loaded nanoemulsion, with an average size of 2.57 ± 0.92 μm. High encapsulation efficiency was observed for DEX (96.19 ± 1.78%), whereas DTX showed moderate retention (52.15 ± 1.08%) after microencapsulation. In vitro release studies indicated a diffusion-controlled release mechanism. Cytotoxicity assays revealed that both the free drugs and the encapsulated system showed cytotoxic activity against HCT-116 colorectal carcinoma cells, whereas no cytotoxicity was observed for the encapsulated system in the L929 cell line. Overall, the system developed represents a promising strategy for the simultaneous delivery of different drugs.
No takes yet. Share an insight, caveat, or question.
Martins et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: